Dissolution of poorly water-soluble drugs in biphasic media using USP 4 and fiber optic system

Clinical Research and Regulatory Affairs

Volumn 26, Issue 1-2, 2009, Pages 8-19

  Vangani, Saroj ^a,b   Li, Xiaoling ^a   Zhou, Peter ^b   Del Barrio, Mary Anne ^b   Chiu, Rick ^b   Cauchon, Nina ^b   Gao, Ping ^b   Medina, Cesar ^b   Jasti, Bhaskara ^a  

^a UNIVERSITY OF THE PACIFIC   (United States)

^b AMGEN INC   (United States)

Author keywords

Absorption; Bioequivalence; Biphasic; Dissolution; Dissolution rate; In vitro in vivo correlation; In vitro in vivo relationship; In vitro model; Nonanol; USP 4

Indexed keywords

ANALGESIC AGENT; CARBAMAZEPINE; GRISEOFULVIN; MEVINOLIN; N [4 [6 [4 (TRIFLUOROMETHYL)PHENYL] 4 PYRIMIDINYLOXY]BENZOTHIAZOL 2 YL]ACETAMIDE;

ANIMAL EXPERIMENT; AQUEOUS SOLUTION; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG CAPSULE; DRUG FORMULATION; DRUG SOLUBILITY; FIBER OPTICS; MALE; MONKEY; NONHUMAN; TABLET;

EID: 72449210513     PISSN: 10601333     EISSN: 15322521     Source Type: Journal    
DOI: 10.1080/10601330902905887     Document Type: Article

References (29)

1. Levy G. Effect of dissolution rate on absorption, metabolism, and pharmacological activity of drugs. J Mond Pharm. 1967;3:237-254.
2. Dressman JB, Amidon GL, Reppas C, Shah VP. Dissolution as a prognostic tool for oral drug absorption: Immediate release dosage forms. Pharm Res. 1988;15:11-22.
3. Guidance for industry. Conduct of bioavailability and bioequivalence studies-Part A: Oral dosage formulations for systemic effects. Health Canada, 1992.
4. "USP General Chapter 1088- In-vitro and in-vivo evaluation of dosage forms", 2004. United States Pharmacopeia and National Formulary, United States Pharmacopeial Convention, Inc., 29th edition:2513-2518.
5. Rohrs BR. Dissolution method development for poorly water soluble compounds. Dissolution technologies. 2001;8:1-5.
6. Gibaldi M, Feldman S. Establishment of sink conditions in dissolution rate experiments. J Pharm Sci. 1967;56:1238-1242.
7. USP General Chapter 711 Dissolution of solid oral dosage forms. 2004. United States Pharmacopeia and National Formulary, United States Pharmacopeial Convention, Inc., 29th edition, 2004.
8. Grundy JS, Anderson KE, Rogers JA, Foster RT. Studies on dissolution testing of the Nifedipine gastrointestinal therapeutic system. I. Description of two-phase in-vitro dissolution test. J of Controlled Release. 1997;48:1-8.
9. Pillay V, Fassihi R. A new method for dissolution studies of lipid-filled capsules employing Nifedipine as a model drug. Pharm Res. 1999;16(2):333-337.
10. Chaudhary RS, Gangwal SS, Gupta VK, Shah YN, Jindal KC, Khanna AS. Dissolution system for nifedipine sustained release formulations. Drug Dev Ind Pharm. 1994;20(7):1267-1274.
11. Qureshi SA, Caille G, Brien R, Piccirilli G, Yu V, Mcgilveray IJ. Application of flow-through dissolution method for the evaluation of oral formulations of Nifedipine. Drug Dev Ind Pharm. 1994;20(11):1869-1882.
12. Bak A, Gore A, Yanez E et al. The co-crystal approach to improve the exposure of an insoluble compound-AMG 517 sorbic acid co-crystal characterization and pharmacokinetics. J Pharm Sci. 2008;23:1-15.
13. Doherty EM, Bannon AW, Bo Y et al. Novel vanilloid receptor- 1 antagonists: Structure-activity relationships in the "A-region" and the selection of a clinical candidate, AMG 517. J Med Chem. 2007;50:3515-3527.
14. Yanez E, Daurio D, Buntich S, Bak A. Physicochemical, solidstate, and pharmacokinetic properties of AMG 517 free base. 2005. Unpublished work.
15. Electronic orange book, Approved drug products with therapeutic equivalence evaluations (http://www.fda.gov/cder/ob/).
16. Almarsson Ö, Zaworotko MJ. Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical cocrystals represent a new path to improved medicines? Chem Commun. 2004;17:1889-1896.
17. Wagner JG, Nelson E. Kinetic analysis of blood levels and urinary excretion in the absorptive phase after single doses of drug. J Pharm Sci. 1964;53:1392-1403.
18. Dissolution tests to predict bioavailability of drugs, 5th International Workshop on Physical Characterization of Pharmaceutical Solids, June 24, 2004, Sandra Klein, Institute of Pharmaceutical Technology, Johann Wolfgang Goethe University, Frankfurt.
19. Stead JA, Freeman M, John EG, Ward GT, Whiting B. Ibuprofen tablets: Dissolution and bioavailability studies. Int J Pharm. 1983;14:59-72.
20. Dressman, JB, 1995; Physiological aspects of the design of dissolution tests. Capsugel seminar, USA.
21. Yunzhe S, Yang R, Zhou W and Xing T. Nimodipine semisolid capsules containing solid dispersion for improving dissolution. Int J Pharm. 2008;359:144-149.
22. Cardot JM, Beyssac E, and Alric M. In vitro-in vivo correlation: Importance of dissolution in IVIVC. Dissolution Technologies. 2007;2:15-19.
23. Stanton MK and Bak A. Physicochemical properties of pharmaceutical co-crystals: A case study of ten AMG 517 co- crystals. Cryst. Growth Des. 2008;8:3856-3862.
24. Krowczynski L. Pharmazie. 1978;33:241-247.
25. Gibaldi M, Feldman S. Establishment of sink conditions in dissolution rate determinations. J Pharm Sci. 1967;56:1238-1242.
26. Grundy JS, Anderson KE, Rogers JA, Fosterb TF. Studies on dissolution testing of the nifedipine gastrointestinal therapeutic system. I. Description of a two-phase in vitro dissolution test. J Controlled Release. 1997;48:9-17.
27. Phillips JG, Chen Y, Wakeling IN. A flow-through dissolution approach to in vivo/in vitro correlation of adinazolam release from sustained release formulations. Drug Dev Ind Pharm. 1989;15:2177-2195.
28. Porges E, Schade B, Ropte W. Automated flow-through method to determine the dissolution rate of slightly soluble substances. Pharm Ind. 1985;47:77-86.
29. Sunesen VH, Pedersen BL, Kristensen HG, Mullertz A. In vivo in vitro correlations for a poorly soluble drug, danazol, using the flow-through dissolution method with biorelevant dissolution media. Eur J Pharm Sci. 2005;24:305-313.